News
2012/4/24: First bedside DNA test to be introduced in Korea
“Spartan Bioscience today announced an exclusive distribution agreement with MilestoneBio for distribution of the first bedside DNA test in Korea.”
2012/3/29: Spartan Bioscience announces publication in Lancet demonstrating clinical usefulness of world’s first bedside DNA test
“Spartan Bioscience today announced publication in Lancet of clinical results from the world’s first bedside DNA test. The paper, ‘Point-of-care genetic testing for personalization of antiplatelet treatment (RAPID GENE)’, reports on the use of the Spartan RX CYP2C19, a simple cheek swab test performed by nurses at the patient’s bedside.”
2011/12/6: Largest clinical trial of point-of-care DNA testing begins in Italy
“Spartan Bioscience today announced the start of GENE-MATRIX—the largest clinical trial to date of point-of-care DNA testing in medicine. The randomized prospective trial will enroll 4,000 patients over 2 years at up to 40 hospitals in Italy.”
2011/11/3: First clinical trial of point-of-care DNA testing in medicine enables cardiac stent patients to receive personalized antiplatelet therapy
“Spartan Bioscience today announced data from the RAPID GENE study showing that point-of-care DNA testing successfully identified patients carrying the CYP2C19*2 gene at the time of cardiac catheterization. Cardiologists were then able to prescribe antiplatelet therapy according to the patient’s genotype. This personalized medicine approach completely eliminated high on-treatment platelet reactivity (HPR) in CYP2C19*2 carriers.”
2011/5/30: Ontario leads clean water research and innovation
“Spartan Bioscience will develop a rapid, on-site water testing system that will reduce analysis times from 72 hours to 2-4 hours, with significant commercial and environmental applications…Ontario is providing over $2.7M to support Spartan Bioscience, as part of a $7.8M project.”
2011/1/10: Spartan Bioscience announces Alere as exclusive distributor for Germany, Austria and Switzerland
“Spartan Bioscience today announces an exclusive distribution agreement with Alere GmbH for distribution of the Spartan RX CYP2C19 in Germany, Austria and Switzerland…Alere will concentrate its efforts on reaching customers in surgery suites and catheterization labs within hospitals and other medical centers.”
